IDG Contributor Network: Price of entry or corporate strategy: how pharma and biotech are approaching digital health


The high costs of drug discovery and commercialization, looming patent cliffs, and increasing regulatory pressure on drug pricing have created a perfect storm of margin and growth pressures on the pharma sector. In an apparent response to these pressures, M&A activity in pharma is back. This month, Bristol-Myers Squibb’s announced its $74 Billion acquisition of Celgene, and Eli Lilly did the same with its $8 Billion acquisition of Loxo. (At the recently concluded JP Morgan Healthcare Conference (JPM), the pharma/biotech sector’s biggest event of the year, Eli Lilly’s CEO indicated that conditions are ripe for an M & A uptick in 2019)

To read this article in full, please click here

Our Location

Our headquarters are located in the heart of the D.C. Metro area:

3309 Wyndham Circle
Alexandria, VA 22302
(203) 982-6389
henry.wicko@solutico.co
Contact Us